ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at http://www.thrombogenics.com.
Important information about forward-looking statements
Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. These forward-looking statements may be identified by references to strategy, plans, objectives, goals, future events or intentions. Forward-looking statements may and often do differ materially from actual results. The company therefore cannot provide any assurance that such forward-looking statements will materialize. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the company's annual report.
For further information please contact:
ThromboGenics NV Tel: +32-16-75-13-10
Chris Buyse, CFO firstname.lastname@example.org
Citigate Dewe Rogerson Tel: +44-(0)-207-638-9571
David Dible/ Nina Enegren/ Sita Shah email@example.com
SOURCE ThromboGenics NV